Skip to content
cccskills
FreePublished on GitHub

endo-pa-repeat-screen-hypokalemia

Recommends correcting serum potassium to the laboratory reference range and repeating aldosterone-to-renin ratio (ARR) screening when the initial screen is negative in a hypertensive patient with hypokalemia. Use when a clinician encounters a negative PA screen in a hypertensive patient with hypokalemia and wonders whether to repeat testing after potassium repletion.

The English summary is being prepared. Showing the original description.

Run score Not tested

See how to install

Files included (1)

  • SKILL.md2.4 KB

SKILL.md (original)

Review the instructions the agent will receive before you install.

Repeat PA screening after correcting hypokalemia if initial screen negative

STEP 1 — Gather Information

Collect serum potassium, plasma aldosterone, plasma renin activity (or direct renin concentration), calculate aldosterone-to-renin ratio (ARR), and review medication list for interfering agents (e.g., MRAs, ACEi, ARBs, diuretics, beta-blockers).

STEP 2 — Rule In / Rule Out

Is serum potassium below the laboratory reference range? If yes, proceed to correct hypokalemia; if no, evaluate for other causes of false-negative PA screen (e.g., interfering medications, suboptimal sample handling).

STEP 3 — Classify or Stratify

After correcting potassium to within the laboratory reference range, repeat PA screening (aldosterone, renin, ARR). If the repeat screen is positive (ARN >20 by immunoassay or >70 by LC-MS/MS-adjusted criteria, with suppressed renin), classify as likely PA; if negative, consider alternative explanations.

STEP 4 — Decide

If repeat screen is positive, initiate PA-specific diagnostic workup (e.g., adrenal venous sampling consideration); if repeat screen remains negative, reassess clinical suspicion and consider repeat screening in future if hypokalemia recurs or hypertension worsens.

Clinical Guardrails / Mimics / Pitfalls

Do not rule out PA based on a single negative screen in hypokalemia; do not repeat PA screening without first correcting potassium to normal range; do not ignore interfering medications that may suppress aldosterone or alter renin; avoid using hemolyzed samples for potassium measurement.

Concrete Clinical Example

A 52-year-old hypertensive patient with serum K+ 2.8 mmol/L has an initial ARR of 15 (immunoassay) with suppressed renin. After KCl repletion to 4.2 mmol/L, repeat ARR is 38 with suppressed renin, prompting adrenal venous sampling.

Source: Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2025, DOI: 10.1210/clinem/dgaf284

TODO: consider adding scripts/calc.py for the endo-pa-repeat-screen-hypokalemia calculator

Reviews

No reviews yet. Tell others what you thought.

Comments

No login needed. Share how it worked for you, ask a question, or note where it did not run.

No comments yet. Be the first to write one.

Comments are published right away. Do not include personal information such as email addresses or phone numbers. Up to 2 URLs.

0 / 1,000 characters

This form is protected by reCAPTCHA, and the Google Privacy Policy and Terms of Service apply.

More skills from this repository

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

See all skills by dromlakhani

Report a problem with this skill